If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...

Johnson & Johnson exec Dr Sarah Siggins has signed on for ASX-listed Algorae Pharmaceuticals’ hunt to create drug ...

Johnson & Johnson exec Dr Sarah ... combined with data on “cannabidiol”, a product derived from medicinal cannabis to determine if the existing drugs could be enhanced by combining them ...

Johnson & Johnson’s rebate model aims to address misuse of 340B Program. HRSA’s threats of penalties led J&J to halt the plan, prompting a legal battle to protect its proposed changes.

Johnson & Johnson and Merck are laying off workers in China, according to a story from Bloomberg which cites reports from ...

When Johnson & Johnson backed down from its proposal to modify the way it supplies certain drugs under the 340B statute, it hinted litigation could be its next step to effect changes that address ...

Johnson & Johnson filed suit against HHS on Tuesday in federal court regarding the agency's 340B program that provides discounted drugs to hospitals and clinics that primarily serve poor and ...

Nov 7 (Reuters) - The U.S. Food & Drug Administration has approved Johnson & Johnson's (JNJ.N), opens new tab device for a type of condition which causes abnormal heart rhythm, the company said on ...

Johnson & Johnson (J&J) has announced that its pan-FGFR tyrosine kinase inhibitor Balversa (erdafitinib) has been granted marketing authorisation by the Medicines and Healthcare products Regulatory ...